Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Exhaled Volatile Organic Compounds as Markers for Medication Use in Asthma

Paul Brinkman, Waqar M. Ahmed, Cristina Gómez, Hugo H. Knobel, Hans Weda, Teunis J. Vink, Tamara M. Nijsen, Craig E. Wheelock, Sven-Erik Dahlen, Paolo Montuschi, Richard G. Knowles, Susanne J. Vijverberg, Anke H. Maitland-van der Zee, Peter J. Sterk, Stephen J. Fowler on behalf of the U-BIOPRED Study Group
European Respiratory Journal 2019; DOI: 10.1183/13993003.00544-2019
Paul Brinkman
1Amsterdam UMC, University of Amsterdam, Department of Respiratory Medicine, Amsterdam Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: p.brinkman@amc.uva.nl
Waqar M. Ahmed
2Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Gómez
3Institute of Environmental Medicine and the Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
4Division of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cristina Gómez
Hugo H. Knobel
5Philips Signify, Eindhoven, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Weda
6Philips Research, Eindhoven, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teunis J. Vink
6Philips Research, Eindhoven, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamara M. Nijsen
6Philips Research, Eindhoven, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig E. Wheelock
4Division of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sven-Erik Dahlen
3Institute of Environmental Medicine and the Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Montuschi
7Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard G. Knowles
8Knowles Consulting, Stevenage Bioscience Catalyst, Stevenage, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne J. Vijverberg
1Amsterdam UMC, University of Amsterdam, Department of Respiratory Medicine, Amsterdam Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anke H. Maitland-van der Zee
1Amsterdam UMC, University of Amsterdam, Department of Respiratory Medicine, Amsterdam Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Sterk
1Amsterdam UMC, University of Amsterdam, Department of Respiratory Medicine, Amsterdam Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen J. Fowler
2Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom
9Manchester Academic Health Science Centre, Manchester University Hospitals NHS Foundation Trust, United Kingdom
10See supplementary U-BIOPRED Study Group Contributors list
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen J. Fowler
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Rationale Asthma is a heterogeneous condition, characterised by chronic inflammation of the airways, typically managed with inhaled bronchodilators and corticosteroids. In case of uncontrolled asthma, oral corticosteroids (OCSs) are often prescribed. Good adherence and inhalation technique are associated with improved outcomes, however it is difficult to monitor appropriate drug intake and effectiveness in individual patients. Exhaled breath contains thousands of volatile organic compounds (VOCs) that reflect changes in the body's chemistry, and may be useful for monitoring drug pharmacokinetics and pharmacodynamics. We aimed to investigate the association of exhaled VOCs in severe asthma patients from the U-BIOPRED cohort (by gas chromatography-time-of-flight-mass spectrometry) with urinary levels of salbutamol and oral corticosteroids (OCS) (by liquid chromatography-high resolution mass spectrometry).

Methods Samples were collected at baseline and after 12–18 months of follow-up. Statistical analysis was based on univariate and multivariate modelling, followed by area under the receiver operating characteristics (AUROC) calculation. Results were verified through longitudinal replication and independent validation.

Results Data were available for 78 patients (baseline: n=48; replication: n=30; validation: n=30). Baseline AUROCs (95% CI) were 82.1 (70.4–93.9) for salbutamol and 78.8 (65.8–91.8) for OCS. These outcomes could adequately be replicated and validated. Additional regression analysis between qualified exhaled VOCs and urinary concentrations of salbutamol and prednisone, showed statistically significant correlations (p<0.01).

Conclusion In summary, we have linked exhaled VOCs to urinary detection of salbutamol and OCS. This merits further development of breathomics into a point of care tool for therapeutic drug monitoring.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Brinkman has nothing to disclose.

Conflict of interest: Dr. Ahmed has nothing to disclose.

Conflict of interest: Dr. Gómez has nothing to disclose.

Conflict of interest: Dr. Knobel reports In addition, Dr. Knobel has a patent Inline drying of breath sample pending.

Conflict of interest: Dr. Weda has nothing to disclose.

Conflict of interest: Dr. Vink has nothing to disclose.

Conflict of interest: Dr. Nijsen has nothing to disclose.

Conflict of interest: Dr. Wheelock has nothing to disclose.

Conflict of interest: Dr. Dahlén reports other from AZ, GSK, Merck, Novartis, Sanofi, Teva, outside the submitted work.

Conflict of interest: Dr. Montuschi has nothing to disclose.

Conflict of interest: Dr. Richard Knowles reports personal fees from Knowles Consulting Ltd, outside the submitted work.

Conflict of interest: Dr. Vijverberg has nothing to disclose.

Conflict of interest: Dr. Maitland-van der Zee reports grants from Boehringer Ingelheim, personal fees from Astra Zeneca, and Chiesi outside the submitted work.

Conflict of interest: Dr. Sterk reports grants from Innovative Medicines Initiative (IMI), during the conduct of the study; other from Scientific Advisor and 4% interest in Breathomix BV, outside the submitted work.

Conflict of interest: Dr. Fowler reports personal fees and non-financial support from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Teva, personal fees from Chiesi, outside the submitted work.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Copyright ©ERS 2019
PreviousNext
Back to top
View this article with LENS
Vol 61 Issue 5 Table of Contents
European Respiratory Journal: 61 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Exhaled Volatile Organic Compounds as Markers for Medication Use in Asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Exhaled Volatile Organic Compounds as Markers for Medication Use in Asthma
Paul Brinkman, Waqar M. Ahmed, Cristina Gómez, Hugo H. Knobel, Hans Weda, Teunis J. Vink, Tamara M. Nijsen, Craig E. Wheelock, Sven-Erik Dahlen, Paolo Montuschi, Richard G. Knowles, Susanne J. Vijverberg, Anke H. Maitland-van der Zee, Peter J. Sterk, Stephen J. Fowler
European Respiratory Journal Jan 2019, 1900544; DOI: 10.1183/13993003.00544-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Exhaled Volatile Organic Compounds as Markers for Medication Use in Asthma
Paul Brinkman, Waqar M. Ahmed, Cristina Gómez, Hugo H. Knobel, Hans Weda, Teunis J. Vink, Tamara M. Nijsen, Craig E. Wheelock, Sven-Erik Dahlen, Paolo Montuschi, Richard G. Knowles, Susanne J. Vijverberg, Anke H. Maitland-van der Zee, Peter J. Sterk, Stephen J. Fowler
European Respiratory Journal Jan 2019, 1900544; DOI: 10.1183/13993003.00544-2019
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Spirometer controlled cine-MRI and TBM in paediatric patients
  • Prior CV disease and mortality COPD pneumonia patients
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society